Genedrive PLC - Holding(s) in Company
Released
Released
Announcement PDF
RNS Number : 9295J
Genedrive PLC
16 April 2020
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
Word format if possible)i
1a. Identity of the issuer or the underlying
issuer of existing shares to which voting
rights are attached ii:
Genedrive PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
X
An acquisition or disposal of financial instruments
X
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name
SPREADEX LTD
City and country of registered office (if applicable)
St Albans, UK
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed
or reached vi:
14/04/2020
6. Date on which issuer notified
(DD/MM/YYYY):
16/04/2020
7. Total positions of person(s) subject to the notification obligation
Resulting situation
% of voting rights
attached to shares
(total of 8. A)
% of voting rights
through financial
instruments
(total of 8.B 1 + 8.B
2)
Total of both in %
(8.A + 8.B)
Total number of voting
5.48%
1.26%
6.74%
34,870,071
rights of issuervii
on the date on
which threshold
was crossed or
reached
Position of
previous
notification (if
applicable)
10.35%
0.19%
10.54%
8. Notified details of the resulting situation on the date on which the threshold was
crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)
Number of voting rightsix
GB00B1VKB244
1,910,000
Direct
% of voting rights
Indirect
(Art 9 of Directive
2004/109/EC) (DTR5.1)
Direct
(Art 10 of Directive
2004/109/EC) (DTR5.2.1)
(Art 9 of Directive
2004/109/EC) (DTR5.1)
5.48%
1,910,000
SUBTOTAL 8. A
Indirect
(Art 10 of Directive
2004/109/EC) (DTR5.2.1)
5.48%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1
(a))
Type of financial
instrument
Expiration
datex
Exercise/
Conversion Periodxi
CFD/Spreadbet
SUBTOTAL 8. B 1
Number of voting rights
that may be acquired if
the instrument is
exercised/converted.
% of voting rights
439,783
1.26%
439,783
1.26%
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of
Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of
financial
instrument
Expiration
date
x
Exercise/
Conversion
Period xi
Physical or
cash
settlementxii
SUBTOTAL
8.B.2
Number of
voting rights
% of voting rights
9. Information in relation to the person subject to the notification obligation (please mark
the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does
not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
X
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal
entityxiv (please add additional rows as necessary)
Namexv
% of voting rights if
it equals or is higher
than the notifiable
threshold
% of voting rights
through financial
instruments if it
equals or is higher
than the notifiable
threshold
Total of both if it
equals or is higher
than the notifiable
threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be
held
11. Additional informationxvi
David Corben
01727895135
Place of
completion
Date of
completion
UK
16/04/2020
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial
Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use
and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLFLFEVSFIRLII
Share your feedback
Discover